Vadim Pivniouk1, Joao A Gimenes-Junior2, Peace Ezeh2, Ashley Michael2, Oksana Pivniouk2, Seongmin Hahn2, Sydney R VanLinden2, Sean P Malone2, Amir Abidov3, Dayna Anderson2, Justyna Gozdz2, Avery DeVries4, Fernando D Martinez4, Christian Pasquali5, Donata Vercelli6. 1. Department of Cellular and Molecular Medicine, The University of Arizona, Tucson, Ariz; Asthma and Airway Disease Research Center, The University of Arizona, Tucson, Ariz; BIO5 Institute, The University of Arizona, Tucson, Ariz. Electronic address: vadimp@arizona.edu. 2. Asthma and Airway Disease Research Center, The University of Arizona, Tucson, Ariz. 3. Medical Student Research Program, College of Medicine, The University of Arizona, Tucson, Ariz. 4. Asthma and Airway Disease Research Center, The University of Arizona, Tucson, Ariz; BIO5 Institute, The University of Arizona, Tucson, Ariz. 5. OM Pharma SA, Geneva, Switzerland. 6. Department of Cellular and Molecular Medicine, The University of Arizona, Tucson, Ariz; Asthma and Airway Disease Research Center, The University of Arizona, Tucson, Ariz; BIO5 Institute, The University of Arizona, Tucson, Ariz; Arizona Center for the Biology of Complex Diseases, The University of Arizona, Tucson, Ariz.
Abstract
BACKGROUND: Microbial interventions against allergic asthma have robust epidemiologic underpinnings and the potential to recalibrate disease-inducing immune responses. Oral administration of OM-85, a standardized lysate of human airways bacteria, is widely used empirically to prevent respiratory infections and a clinical trial is testing its ability to prevent asthma in high-risk children. We previously showed that intranasal administration of microbial products from farm environments abrogates experimental allergic asthma. OBJECTIVES: We sought to investigate whether direct administration of OM-85 to the airway compartment protects against experimental allergic asthma; and to identify protective cellular and molecular mechanisms activated through this natural route. METHODS: Different strains of mice sensitized and challenged with ovalbumin or Alternaria received OM-85 intranasally, and cardinal cellular and molecular asthma phenotypes were measured. Airway transfer experiments assessed whether OM-85-treated dendritic cells protect allergen-sensitized, OM-85-naive mice against asthma. RESULTS: Airway OM-85 administration suppressed allergic asthma in all models acting on multiple innate and adaptive immune targets: the airway epithelium/IL-33/ILC2 axis, lung allergen-induced type 2 responses, and dendritic cells whose Myd88/Trif-dependent tolerogenic reprogramming was sufficient to transfer OM-85-induced asthma protection. CONCLUSIONS: We provide the first demonstration that administering a standardized bacterial lysate to the airway compartment protects from experimental allergic asthma by engaging multiple immune pathways. Because protection required a cumulative dose 27- to 46-fold lower than the one reportedly active through the oral route, the efficacy of intranasal OM-85 administration may reflect its direct access to the airway mucosal networks controlling the initiation and development of allergic asthma.
BACKGROUND: Microbial interventions against allergic asthma have robust epidemiologic underpinnings and the potential to recalibrate disease-inducing immune responses. Oral administration of OM-85, a standardized lysate of human airways bacteria, is widely used empirically to prevent respiratory infections and a clinical trial is testing its ability to prevent asthma in high-risk children. We previously showed that intranasal administration of microbial products from farm environments abrogates experimental allergic asthma. OBJECTIVES: We sought to investigate whether direct administration of OM-85 to the airway compartment protects against experimental allergic asthma; and to identify protective cellular and molecular mechanisms activated through this natural route. METHODS: Different strains of mice sensitized and challenged with ovalbumin or Alternaria received OM-85 intranasally, and cardinal cellular and molecular asthma phenotypes were measured. Airway transfer experiments assessed whether OM-85-treated dendritic cells protect allergen-sensitized, OM-85-naive mice against asthma. RESULTS: Airway OM-85 administration suppressed allergic asthma in all models acting on multiple innate and adaptive immune targets: the airway epithelium/IL-33/ILC2 axis, lung allergen-induced type 2 responses, and dendritic cells whose Myd88/Trif-dependent tolerogenic reprogramming was sufficient to transfer OM-85-induced asthma protection. CONCLUSIONS: We provide the first demonstration that administering a standardized bacterial lysate to the airway compartment protects from experimental allergic asthma by engaging multiple immune pathways. Because protection required a cumulative dose 27- to 46-fold lower than the one reportedly active through the oral route, the efficacy of intranasal OM-85 administration may reflect its direct access to the airway mucosal networks controlling the initiation and development of allergic asthma.
Authors: Marie-Claire Arrieta; Leah T Stiemsma; Pedro A Dimitriu; Lisa Thorson; Shannon Russell; Sophie Yurist-Doutsch; Boris Kuzeljevic; Matthew J Gold; Heidi M Britton; Diana L Lefebvre; Padmaja Subbarao; Piush Mandhane; Allan Becker; Kelly M McNagny; Malcolm R Sears; Tobias Kollmann; William W Mohn; Stuart E Turvey; B Brett Finlay Journal: Sci Transl Med Date: 2015-09-30 Impact factor: 17.956
Authors: Kyle T Mincham; Naomi M Scott; Jean-Francois Lauzon-Joset; Jonatan Leffler; Alexander N Larcombe; Philip A Stumbles; Sarah A Robertson; Christian Pasquali; Patrick G Holt; Deborah H Strickland Journal: J Clin Invest Date: 2018-10-02 Impact factor: 14.808
Authors: Christina A Christianson; Nicholas P Goplen; Iram Zafar; Chaoyu Irvin; James T Good; Donald R Rollins; Balachandra Gorentla; Weimin Liu; Magdalena M Gorska; HongWei Chu; Richard J Martin; Rafeul Alam Journal: J Allergy Clin Immunol Date: 2015-01-21 Impact factor: 10.793
Authors: Charlotte Braun-Fahrländer; Josef Riedler; Udo Herz; Waltraud Eder; Marco Waser; Leticia Grize; Soyoun Maisch; David Carr; Florian Gerlach; Albrecht Bufe; Roger P Lauener; Rudolf Schierl; Harald Renz; Dennis Nowak; Erika von Mutius Journal: N Engl J Med Date: 2002-09-19 Impact factor: 91.245
Authors: Kei E Fujimura; Alexandra R Sitarik; Suzanne Havstad; Din L Lin; Sophia Levan; Douglas Fadrosh; Ariane R Panzer; Brandon LaMere; Elze Rackaityte; Nicholas W Lukacs; Ganesa Wegienka; Homer A Boushey; Dennis R Ownby; Edward M Zoratti; Albert M Levin; Christine C Johnson; Susan V Lynch Journal: Nat Med Date: 2016-09-12 Impact factor: 53.440
Authors: Krist Helen Antunes; Gisele Cassão; Leonardo Duarte Santos; Sofia Giacomet Borges; Juliana Poppe; João Budelon Gonçalves; Eduarda da Silva Nunes; Guilherme Fernando Recacho; Vitória Barbosa Sousa; Gabriela Souza Da Silva; Daniel Mansur; Renato T Stein; Christian Pasquali; Ana Paula Duarte De Souza Journal: Front Immunol Date: 2022-05-05 Impact factor: 8.786
Authors: Roos E M Verstegen; Atanaska I Kostadinova; Zenebech Merenciana; Johan Garssen; Gert Folkerts; Rudi W Hendriks; Linette E M Willemsen Journal: Nutrients Date: 2021-11-19 Impact factor: 5.717